Base editing shows promise for treating sickle cell disease and beta thalassemia

Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia.

Related Keywords

United States ,American ,Lily Ramsey ,Senthil Velan Bhoopalan ,Cicera Lazzarotto ,Guolian Kang ,Yong Cheng ,Phillip Doerfler ,Erin Dempsey ,Mitchell Weiss ,Gregory Newby ,Ruopeng Feng ,Yu Yao ,Rachel Levine ,Jingjing Zhang ,Shengdar Tsai ,Henry Bell ,Yoonjeong Jang ,Jingjing Chen ,Richard Merkin ,Kalin Mayberry ,Merlin Crossley ,David Liu ,Thiyagaraj Mayuranathan ,John Tisdale ,Yichao Li ,Shaina Porter ,Akshay Sharma ,Nikitha Nimmagadda ,Shondra Pruett Miller ,Jude Department Of Hematology ,Jude Collaborative Research Consortium ,Cooley Anemia Foundation Postdoctoral Research Fellowship Award ,Howard Hughes Medical Institute ,Assisi Foundation Of Memphis ,Jude Children Research Hospital ,Blood Institute ,Broad Institute ,American Society Of Hematology ,University Of New South Wales ,National Heart ,Doris Duke Foundation ,National Institutes Of Health ,Melinda Gates Foundation ,Molecular Therapeutics Branch ,National Institute Of Diabetes ,Jude Children ,Research Hospital ,Therapeutic Genome Engineering ,Jude Therapeutic Genome Engineering ,Jude Department ,New South Wales ,National Institute ,National Institutes ,Helen Hay Whitney Postdoctoral Fellowship ,Assisi Foundation ,American Society ,